lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-25. Numbers and descriptions here follow the published literature rather than marketing material.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
=== Preclinical === AC-203 – unspecified – alopecia areata – cell death modulator ADA-308 – topical – alopecia – androgen receptor antagonist BMD-1141 (BMD-1341) – subcutaneous injection – alopecia – parathyroid hormone receptor agonist Crebankitug (ZB-168) – parenteral – alopecia areata – interleukin 7 receptor α subunit inhibitor, thymic stromal lymphopoietin inhibitor CS-12192 – oral – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 3 inhibitor, TBK1 protein inhibitor ES-135 – parenteral – alopecia – fibroblast growth factor replacement FB-102 – unknown – alopecia areata – interleukin-2 receptor β subunit antagonist HCW-9302 – injection – alopecia areata – interleukin 2 replacement MAX-40070 (MAX-3) – topical – alopecia areata – Janus kinase inhibitor, TYK2 kinase inhibitor MEI-004 – unknown – alopecia – undefined mechanism of action Oxymetazoline (DA-020) – topical – alopecia – α1-adrenergic receptor agonist Phenylephrine/synephrine/tyramine (DA-007) – topical – alopecia – combination of phenylephrine (α1-adrenergic receptor agonist), synephrine (α1-adrenergic receptor agonist), and tyramine (norepinephrine–dopamine releasing agent) YR-001 – topical – alopecia – ion channel antagonist
=== United States === In an exchange on X, Vice President JD Vance stated, "Killing cartel members who poison our fellow citizens is the highest and best use of our military," to which writer Brian Krassenstein responded, "killing the citizens of another nation who are civilians without any due process is called a war crime"; Vance responded "I don't give a shit what you call it." Senator Rand Paul intervened in the argument, saying "What a despicable and thoughtless sentiment it is to glorify killing someone without a trial." Senator Bernie Moreno responded to Paul saying, "what's really despicable is defending foreign terrorist drug traffickers who are directly responsible for the deaths of hundreds of thousands of Americans in Kentucky and Ohio." The initial strike was welcomed by Republican senators Lindsey Graham and Bernie Moreno, with Moreno saying that "Sinking [the] boat saved American lives." Senator Mark Warner said he was worried about putting American sailors "in harm's way by violating international law", and declared that neither he, a member of the Gang of Eight, nor the Senate Intelligence Committee were briefed ahead of the operation. A bipartisan briefing scheduled for 5 September was abruptly canceled. Warner condemned the government's briefing procedures again on 29 October. When asked for comment in response, a White House spokesperson accused the Democratic Party of "running cover for foreign drug smugglers."
== History == Beginning in 2007, the British Engineering and Physical Sciences Research Council has funded development of ribosome-like molecular assemblers. Clearly, molecular assemblers are possible in this limited sense. A technology roadmap project, led by the Battelle Memorial Institute and hosted by several U.S. National Laboratories has explored a range of atomically precise fabrication technologies, including both early-generation and longer-term prospects for programmable molecular assembly; the report was released in December, 2007. In 2008, the Engineering and Physical Sciences Research Council provided funding of £1.5 million over six years (£1,942,235.57, $2,693,808.00 in 2021) for research working towards mechanized mechanosynthesis, in partnership with the Institute for Molecular Manufacturing, amongst others. Likewise, the term "molecular assembler" has been used in science fiction and popular culture to refer to a wide range of fantastic atom-manipulating nanomachines. Much of the controversy regarding "molecular assemblers" results from the confusion in the use of the name for both technical concepts and popular fantasies. In 1992, Drexler introduced the related but better-understood term "molecular manufacturing", which he defined as the programmed "chemical synthesis of complex structures by mechanically positioning reactive molecules, not by manipulating individual atoms". This article mostly discusses "molecular assemblers" in the popular sense.
== History == Menthol was first isolated in 1771, by the German, Hieronymus David Gaubius. Early characterizations were done by Oppenheim, Beckett, Moriya, and Atkinson. It was named by F. L. Alphonse Oppenheim (1833–1877) in 1861.
On taking office, Biden unveiled the U.S. Citizenship Act of 2021 and moved to dismantle several policies implemented under Donald Trump, halting construction of the Mexico–United States border wall, ending Trump's travel ban on countries with predominantly Muslim populations, and signing an executive order to reaffirm protections for DACA recipients. The Department of Homeland Security narrowed the scope of interior immigration enforcement, directing Immigration and Customs Enforcement (ICE) to prioritize national security and violent crime concerns. Illegal border crossings at the Mexico–United States border began to surge in 2021 when Biden assumed office, reaching an all-time monthly high in December 2023. Throughout 2024, crossings began to significantly decline from the December record, after Biden implemented restrictions on asylum claims from migrants who cross the border between ports of entry and urged Mexico to crack down on migrants. Deportations from October 2023 to September 2024 reached the highest level since 2014. Biden used humanitarian parole to mitigate illegal border crossings, allowing migrants to fly into the U.S. or schedule their entries through official entry points in the U.S.-Mexico border. Over a million migrants had been admitted to the U.S. under humanitarian parole as of January 2024. Between January 2021 and January 2024, the US Border Patrol confirmed more than 7.2 million illegal migrants trying to cross the Mexico–United States border, not counting gotaways. 2023 was a record year, with over 2.5 million encounters.
Sources: en.wikipedia.org
=== Surgery === Bariatric surgical procedures are increasingly used amongst adolescents with severe adolescent obesity to promote weight loss. Laparoscopic adjustable gastric banding showed greater weight loss than lifestyle management in a small study. Roux-en-Y gastric bypass and vertical sleeve gastrectomy are two surgical procedures currently used in adolescent obesity with varying success rates. The two types of procedures have shown a 26% weight loss from baseline at five years with an 86% remission rate in diabetes and 68% hypertension remission rate. Of those adolescents who lost weight after bariatric surgery, 60% maintained at least a 20% weight loss at five-year follow-up and 8% had regained most of the pre-surgical weight. Lack of pre-surgical weight loss is associated with an increased risk of weight gain after bariatric surgery. Other risks of bariatric surgery in adolescents may include nutrient deficiencies (including vitamin B12, folate and iron), the risk of bone mass loss, and a questionable risk of alcohol use disorders later in life.
== Pathogenesis == The exact cause for the varied collection of symptoms found in the different ALD phenotypes is not clear. The white matter of the brain, the Leydig cells of the testes and the adrenal cortex are the most severely affected systems. The excess VLCFA can be detected in almost all tissues of the body, despite the localization of symptoms. The lack of Coenzyme A does not permit the disintegration of the VLCFA, accumulating the same in the white matter, adrenal glands, and the testes more specifically in the Leydig cells not allowing the proper function of these organs. Successful treatment of the demyelination process that affects the brain with either stem cell transplant or gene therapy does not immediately normalize the VLCFA levels in body tissues. The levels of VLCFA can be normalized by treatment with Lorenzo's oil, but this does not alter the progression of the disease. It is unclear whether the accumulation of VLCFA is associated with the pathogenesis of the disease in a specific way, or if it is a biochemical phenotype, useful for identification. Several studies link inflammation from viral infection or head trauma to development or worsening of symptoms.
== Function == In diderm bacteria, the periplasm contains a thin cell wall composed of peptidoglycan. In addition, it includes solutes such as ions and proteins, which are involved in wide variety of functions ranging from nutrient binding, transport, folding, degradation, substrate hydrolysis, to peptidoglycan synthesis, electron transport, and alteration of substances toxic to the cell (xenobiotic metabolism). Importantly, the periplasm is devoid of ATP. Several types of enzyme are present in the periplasm including alkaline phosphatases, cyclic nucleotide phosphodiesterases, acid phosphatases and 5'-nucleotidases. Of note, the periplasm also contains enzymes important for the facilitation of protein folding. For example, disulfide bond protein A (DsbA) and disulfide bond protein C (DsbC), which are responsible for catalyzing peptide bond formation and isomerization, respectively, were identified in the periplasm of E. Coli. As disulfide bond formation is frequently a rate-limiting step in the folding of proteins, these oxidizing enzymes play an important role in the bacteria periplasm. In addition, the periplasm mediates the uptake of DNA in several strains of transformable bacteria.
== Age-related prevalence of the CKM syndrome == A study of 231,590,853 individuals living in the USA found older aged patients trended to have higher stages of the CKM syndrome. In the 20-44 years old age group 17.3% were stage 0, 37.6% were stage 1, 43.2% % were stage 2, 0.2% were stage 3, and 1.7% were stage 4. In the 45 to 64 years old group, 5.4% were stage 0, 21.0% were stage 1, 63.8% were stage 2, 1.2 % were stage 3, and 8.6% were stage 4. In the 65 years and older age group, 1.8% were stage 0, 8.4% were stag 1, 39.0% were stage 2, 24.6% were stage 3, and 26.2% were stage 4. The 20 to 44, 45 to 64, and 65 or greater years old groups consisted respectively of 104,113,793, 82,640,261, and 44,836,799 individuals.
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
Chemical degradation such as hydrolysis and oxidation proceeds more slowly as temperature falls. Cold storage also limits microbial growth in reconstituted material. Repeated warming should be avoided because thermal cycling stresses the peptide.